Search

Displaying results 3311 - 3320 of 7285 in total
  1. Drug

    Zemprocitinib

    go.drugbank.com/drugs/DB21719
    Experimental

    Zemprocitinib has a monoisotopic molecular weight of 345.13 Da. … Zemprocitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Zemprocitinib is a Janus kinase inhibitor.

  2. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004.

  3. Drug

    Testosterone enanthate

    go.drugbank.com/drugs/DB13944
    ApprovedInvestigational

    As recent as 1 October 2018, the US FDA approved Antares Pharma Inc.' … Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate.

  4. Target

    Cytochrome c oxidase subunit FA4

    go.drugbank.com/bio_entities/BE0000169
    TargetHumans

    The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … COXFA4 is required for complex IV maintenance (PubMed:22902835)

    Synonyms: Complex I-MLRQ
  5. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.

  6. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    [FDA Label] This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. … results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes.

  7. Drug

    Fluoxetine

    go.drugbank.com/drugs/DB00472
    ApprovedInvestigationalVet approved

    Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). … [A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies

    Products: FLUOXETIN 10 1A PHARMA, FLUOXETIN 20 1A PHARMA
  8. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol]. … [L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]

  9. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809] … Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.

    Mixtures: FOLISTER COMPLEX HAIR LOTION (R), FOLISTER COMPLEX HAIR LOTION (R)
  10. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].